Petros Pharma Files S-1/A Amendment

TL;DR

Petros Pharma dropped an S-1/A update on 2/13/25 - check the financials for private placement details.

AI Summary

Petros Pharmaceuticals, Inc. filed an S-1/A amendment on February 13, 2025, related to its registration statement. The filing includes financial data points such as a risk-free interest rate, price volatility, expected term, and expected dividend rate, all associated with private placements as of December 31, 2023, and July 13, 2023.

Why It Matters

This S-1/A filing provides updated information for investors regarding Petros Pharmaceuticals' financial status and potential securities offerings, impacting investment decisions.

Risk Assessment

Risk Level: medium — S-1/A filings often indicate potential stock dilution or changes in company structure, which can introduce investment risk.

Key Numbers

• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
• 174 — Public Document Count (Indicates the volume of documents associated with this filing)

Key Players & Entities

• Petros Pharmaceuticals, Inc. (company) — Filer of the S-1/A
• 20250213 (date) — Filing date of the S-1/A
• 333-284495 (dollar_amount) — SEC file number
• 2023-12-31 (date) — Fiscal year end and date for financial inputs
• 2023-07-13 (date) — Date for financial inputs

FAQ

Key Financial Figures

• $0.0001 — sting of one share of our common stock, $0.0001 par value per share ("common stock"), a
• $0.269 — at the assumed public offering price of $0.269 per Unit, which was the last reported s
• $0.24 — stock on The Nasdaq Capital Market was $0.24 per share. We are an "emerging growth
• $125,000 — t-of-pocket expenses in an amount up to $125,000. See " Plan of Distribution " for a des

Filing Documents

• tmb-20240930xs1a.htm (S-1/A) — 4886KB
• tmb-20240930xex3d11.htm (EX-3.11) — 136KB
• tmb-20240930xex4d7.htm (EX-4.7) — 175KB
• tmb-20240930xex4d8.htm (EX-4.8) — 158KB
• tmb-20240930xex5d1.htm (EX-5.1) — 23KB
• tmb-20240930xex10d20.htm (EX-10.20) — 246KB
• tmb-20240930xex23d1.htm (EX-23.1) — 3KB
• tmb-20240930xex23d2.htm (EX-23.2) — 7KB
• tmb-20240930xexfees.htm (EX-FILING FEES) — 113KB
• tmb-20240930xs1a002.jpg (GRAPHIC) — 12KB
• 0001410578-25-000122.txt ( ) — 21198KB
• tmb-20240930.xsd (EX-101.SCH) — 125KB
• tmb-20240930_cal.xml (EX-101.CAL) — 77KB
• tmb-20240930_def.xml (EX-101.DEF) — 499KB
• tmb-20240930_lab.xml (EX-101.LAB) — 782KB
• tmb-20240930_pre.xml (EX-101.PRE) — 960KB
• tmb-20240930xs1a_htm.xml (XML) — 3047KB

USE OF PROCEEDS

USE OF PROCEEDS 42 MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS 43 CAPITALIZATION 44

DILUTION

DILUTION 46 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS 48

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 51

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 57 MATERIAL US FEDERAL INCOME TAX CONSEQUENCES 65 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 72 PLAN OF DISTRIBUTION 73

MANAGEMENTS DISCUSSION AND ANALYSIS

MANAGEMENTS DISCUSSION AND ANALYSIS 80 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 103 EXECUTIVE AND DIRECTOR COMPENSATION 110 PRINCIPAL STOCKHOLDERS 114 EXPERTS 117 LEGAL MATTERS 117 WHERE YOU CAN FIND MORE INFORMATION 117

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS The registration statement on Form S-1, which we filed with the Securities and Exchange Commission (the "SEC") and of which this prospectus forms a part, includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC before making your investment decision. You should rely only on the information provided in this prospectus. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained in this prospectus in making your investment decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading "Where You Can Find Additional Information." We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no as

View Full Filing

View this S-1/A filing on SEC EDGAR